title: [BCG in superficial carcinoma of the bladder. Authors' experience].
abstract: Contribution of 95 patients with surface vesical tumour managed with UTR and endovesical BCG. The response was absence of recurrence in 68.4% cases in Ta stage, 63% in T1 and 66.7% in 'in situ' carcinoma. Therapy tolerability was good, with few side-effects. We conclude that BCG endovesical instillation as co-adjunctive therapy to UTR in surface vesical tumours has been shown to be effective for the period under study.
authors.affiliation: Servicio de Urología, Hospital de Bellvitge, Ciudad Sanitaria Princeps d'Espanya, Barcelona.
authors.forename: J R
authors.initials: JR
authors.lastname: Bordalba Gómez
authors.forename: J
authors.initials: J
authors.lastname: Muñoz Segui
authors.forename: F
authors.initials: F
authors.lastname: Aguilo
authors.forename: A
authors.initials: A
authors.lastname: Gil Vernet
authors.forename: F
authors.initials: F
authors.lastname: Vigues
authors.forename: M A
authors.initials: MA
authors.lastname: Lopez Costea
authors.forename: N
authors.initials: N
authors.lastname: Serrallach
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D001500:BCG Vaccine / Q000008:administration & dosage*; D002278:Carcinoma in Situ / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000517:prevention & control; D009367:Neoplasm Staging; D011468:Prostatectomy; D013852:Thiotepa / Q000008:administration & dosage; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
chemical_list: D001500:BCG Vaccine; D013852:Thiotepa
vernacular_title: BCG en el carcinoma vesical superficial. Nuestra experiencia.